CEACAM5 Drugs Market Outlook: Rising Cancer Cases and Clinical Trials to Fuel Growth by 2034 | DelveInsight

The CEACAM5 drugs market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer and the increasing number of CEACAM5 that are under clinical trials. Currently, there are no CEACAM5 approved by any regulatory bodies.

LAS VEGAS, Sept. 17, 2024 /PRNewswire/ -- DelveInsight's CEACAM5 Drugs Market Insights report includes a comprehensive understanding of current treatment practices, emerging CEACAM5 drugs, market share of individual therapies, and current and forecasted CEACAM5 drugs market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the CEACAM5 Market Report

• As per DelveInsight's analysis, the total market size of CEACAM5 drugs in the 7MM is expected to surge significantly by 2034.
• Leading CEACAM5 drug companies such as SurgiMab, Merck KGaA, Sanofi, Hoffmann-La Roche, and others are developing novel CEACAM5 drugs that can be available in the CEACAM5 drugs market in the coming years.
• Some of the key CEACAM5 drugs in the pipeline include SGM-101, M9140, SGN-CEACAM5C, Cibisatamab + RO7122290, and others.
• In June 2024, Merck KGaA shared preliminary data from a Phase I study of M9140, a novel antibody-drug conjugate (ADC) targeting CEACAM5, at the American Society of Clinical Oncology (ASCO) Annual Meeting. This trial included 40 patients with advanced colorectal cancer who had previously undergone treatment, from the U.S., Europe, and Japan, and tested across seven different dose levels. The results showed that 10% of patients experienced a partial response, while 42.5% achieved stable disease. With a preliminary median progression-free survival of 6.7 months, these findings indicate that M9140 could represent a promising new treatment option for this condition.
• In December 2023, Sanofi ended its tusamitamab ravtansine program as it missed the study's primary endpoint and did not beat the chemotherapy docetaxel when it came to progression-free survival. Tusamitamab ravitansine (CEACAM5) was originated from a long-running deal between Sanofi and ImmunoGen and evaluated as a monotherapy in previously treated patients with metastatic non-squamous non-small cell lung cancer (NSCLC).

Discover which therapies are expected to grab the CEACAM5 drugs market share @ CEACAM5 Drugs Market Report

CEACAM5 Drugs Market Dynamics

The CEACAM5 drugs market is rapidly evolving due to the molecule's significance in the treatment of various cancers, particularly colorectal, gastric, and non-small cell lung cancers. One of the primary drivers of the CEACAM5 drugs market is the increasing prevalence of cancers that overexpress CEACAM5. As cancer rates continue to rise globally, the demand for more effective and targeted therapies is growing, propelling the market forward. Furthermore, advancements in biotechnology and immunotherapy are enabling the development of innovative CEACAM5-targeting drugs, which are showing promise in clinical trials. These advancements are expected to expand the market significantly in the coming years.

However, the CEACAM5 drugs market also faces challenges. One significant barrier is the high cost of drug development and the stringent regulatory requirements for new therapies. The complex nature of biologics and the need for extensive clinical testing before approval can lead to high development costs, which are often passed on to consumers, limiting access to these therapies. Additionally, the competition from other targeted therapies and the development of resistance to current treatments may pose further challenges to the growth of the market.

Despite these challenges, the market outlook for CEACAM5-targeting drugs remains positive. As research continues to uncover more about the role of CEACAM5 in cancer progression, new therapeutic opportunities are likely to emerge. Collaborations between pharmaceutical companies and research institutions are expected to accelerate the discovery and development of next-generation CEACAM5 therapies, potentially leading to more effective treatments with fewer side effects.

CEACAM5 Drugs Treatment Market 

Therapies that specifically target CEACAM5 have not yet received regulatory approval. However, researchers are actively investigating various strategies to inhibit CEACAM5 as a potential treatment for cancers that overexpress this protein. Some of the approaches under investigation include:

Small Molecule Inhibitors: Companies are developing small molecules aimed at inhibiting CEACAM5 activity in Non-Small Cell Lung Cancer. These inhibitors could potentially disrupt CEACAM5-related signaling pathways involved in cancer progression.

Antibodies Blocking CEACAM5: Monoclonal antibodies are being engineered to bind specifically to CEACAM5, thereby blocking its function. This could potentially inhibit tumor growth and metastasis by disrupting CEACAM5-related processes.

Peptide-based Inhibitors: Peptides designed from the CEACAM5 protein sequence or mimicking its binding partners are being explored as potential inhibitors. These peptides could interfere with CEACAM5-related cell adhesion, migration, and invasion.

Gene Silencing: Techniques such as RNA interference (RNAi) or CRISPR-based gene editing are being explored to silence CEACAM5 expression in cancer cells. Reducing CEACAM5 levels could potentially inhibit cancer cell growth and metastasis.

Combination Therapies: Inhibiting CEACAM5 could be combined with other targeted therapies, chemotherapy, or immunotherapy to enhance treatment effectiveness. These combination approaches might provide synergistic effects and help overcome resistance mechanisms.

Learn more about the FDA-approved CEACAM5 drugs @ CEACAM5 Drugs

Key Emerging CEACAM5 Drugs and Companies

Merck KGaA, Sanofi, SurgiMab, Roche, and several other companies are currently engaged in the development and production of selective CEACAM5 ADCs, which have the potential to significantly impact and enhance the CEACAM5 market.

SGM-101 is a tumor-targeting antibody linked to a near-infrared fluorochrome. It specifically binds to a marker that is overexpressed in gastrointestinal and other types of tumors. Currently, in Phase III trials, it is being evaluated for its effectiveness in identifying primary and recurrent tumors, as well as metastases, in patients undergoing colorectal cancer surgery.

This near-infrared fluorochrome targets the CEACAM5 receptor, which is utilized in molecular imaging to guide lung cancer resections, particularly because the glycoprotein is present in over 80% of adenocarcinomas.

M9140 is an experimental antibody-drug conjugate targeting CEACAM5, designed to deliver a cytotoxic topoisomerase 1 (TOP1) inhibitor to tumor cells expressing CEACAM5. This inhibitor enters the cell nucleus, disrupting DNA replication and repair, leading to the death of the targeted tumor cells. Additionally, the payload can kill nearby tumor cells through a bystander effect. M9140 is engineered for stability in the bloodstream, with enhanced cancer-killing efficiency and a wide therapeutic window. It also shows potential for synergy when combined with DDR inhibition.

The anticipated launch of these emerging therapies are poised to transform the CEACAM5 drugs market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CEACAM5 drugs market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about CEACAM5 drugs clinical trials, visit @ CEACAM5 Treatment Drugs 

CEACAM5 Overview

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5) is a glycoprotein that belongs to the immunoglobulin superfamily and plays a significant role in cell adhesion, intracellular signaling, and immune response regulation. It is highly expressed in various epithelial cells, particularly in the gastrointestinal tract, lungs, and pancreas. CEACAM5 is best known for its association with carcinoembryonic antigen (CEA), a well-established tumor marker used in the diagnosis and management of certain types of cancer, including colorectal, gastric, and pancreatic cancers. Elevated levels of CEACAM5 in the blood are often indicative of malignant tumors, making it a valuable biomarker for cancer detection and monitoring.

CEACAM5's role extends beyond its use as a diagnostic marker; it is also involved in tumorigenesis and metastasis. The molecule can mediate cell-cell and cell-matrix interactions, which are crucial for the proliferation and spread of cancer cells. Due to its overexpression in various cancers and limited expression in normal tissues, CEACAM5 has become a target for therapeutic interventions, including monoclonal antibodies and cancer vaccines. Ongoing research continues to explore the potential of CEACAM5-targeted therapies, aiming to improve the specificity and efficacy of cancer treatment while minimizing damage to healthy tissues.

CEACAM5 Epidemiology Segmentation

The CEACAM5 drugs market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases in Selected Indications for CEACAM5-specific Therapies 
• Total Eligible Patient Pool for CEACAM5-specific Therapies in Selected Indications 
• Total Treated Cases in Selected Indications for CEACAM5-specific Therapies 

Scope of the CEACAM5 Market Report

• CEACAM5 Therapeutic Assessment: CEACAM5 current marketed and emerging therapies
• CEACAM5 Market Dynamics: Conjoint Analysis of Emerging CEACAM5 Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, CEACAM5 Market Access and Reimbursement

Discover more about CEACAM5 drugs in development @ CEACAM5 Drugs Clinical Trials

Table of Contents

Related Reports

Colorectal Cancer Market

Colorectal Cancer Market Insight, Epidemiology and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies, including Mirati Therapeutics, Merck, Hutchison Medipharma, EpicentRx, Eli Lilly, Amgen, Daiichi Sankyo, AstraZeneca, Cardiff Oncology, NeoImmuneTech, among others.

Colorectal Cancer Pipeline

Colorectal Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key colorectal cancer companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, among others.

Metastatic Colorectal Cancer Pipeline

Metastatic Colorectal Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic colorectal Cancer companies, including Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, among others.

Metastatic Colorectal Cancer Market

Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies, including Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, AB Science, Daiichi Sankyo, Astrazeneca, Merck, Eisai, Mirati Therapeutics, Cardiff Oncology, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg